CA2238875C - Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv - Google Patents

Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv Download PDF

Info

Publication number
CA2238875C
CA2238875C CA002238875A CA2238875A CA2238875C CA 2238875 C CA2238875 C CA 2238875C CA 002238875 A CA002238875 A CA 002238875A CA 2238875 A CA2238875 A CA 2238875A CA 2238875 C CA2238875 C CA 2238875C
Authority
CA
Canada
Prior art keywords
6alkyl
independently selected
ethyl
pyridyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002238875A
Other languages
English (en)
Other versions
CA2238875A1 (fr
Inventor
Daniel Guay
Yves Girard
Yves Ducharme
Marc Blouin
Pierre Hamel
Mario Girard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Frosst Canada and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606377.1A external-priority patent/GB9606377D0/en
Application filed by Merck Frosst Canada and Co filed Critical Merck Frosst Canada and Co
Publication of CA2238875A1 publication Critical patent/CA2238875A1/fr
Application granted granted Critical
Publication of CA2238875C publication Critical patent/CA2238875C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Nouveau composé de formule (I) utilisé pour traiter des maladies, y compris l'asthme, par augmentation du niveau d'adénosine-3',5'-monophosphate cyclique (cAMP), cette augmentation étant obtenue par l'inhibition de la phosphodiestérase IV (PDE IV). L'invention se rapporte également à certaines compositions pharmaceutiques et à des méthodes de traitement des maladies par inhibition de la PDE IV, entraînant une augmentation de cAMP, ces méthodes consistant à utiliser des composés de la formule (I).
CA002238875A 1995-12-15 1996-12-11 Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv Expired - Fee Related CA2238875C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US870495P 1995-12-15 1995-12-15
US60/008,704 1995-12-15
GB9606377.1 1996-03-26
GBGB9606377.1A GB9606377D0 (en) 1996-03-26 1996-03-26 Tri-aryl ethane derivatives as PDE IV inhibitors
PCT/CA1996/000839 WO1997022586A1 (fr) 1995-12-15 1996-12-11 Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv

Publications (2)

Publication Number Publication Date
CA2238875A1 CA2238875A1 (fr) 1997-06-26
CA2238875C true CA2238875C (fr) 2003-09-16

Family

ID=26308993

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002238875A Expired - Fee Related CA2238875C (fr) 1995-12-15 1996-12-11 Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv

Country Status (5)

Country Link
EP (1) EP0873311A1 (fr)
JP (1) JP3465825B2 (fr)
AU (1) AU707574B2 (fr)
CA (1) CA2238875C (fr)
WO (1) WO1997022586A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69826286T2 (de) * 1997-06-27 2005-11-24 Fujisawa Pharmaceutical Co., Ltd. Derivate mit einem aromatischen ring
AU754253B2 (en) 1998-10-06 2002-11-07 Dainippon Pharmaceutical Co. Ltd. 2,3-disubstituted pyridine derivatives, processes for the preparation thereof, pharmaceutical compositions containing the same and intermediates therefor
US6180650B1 (en) * 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6200993B1 (en) * 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
EP1212089B1 (fr) 1999-08-21 2006-03-22 ALTANA Pharma AG Combinaison synergetique de roflumilast et salmeterol
AU2002229611A1 (en) * 2000-12-08 2002-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells
ES2427930T3 (es) 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
KR20040007596A (ko) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 골절 치료 촉진용 조성물
AU2003295656B2 (en) * 2002-11-19 2010-11-11 Memory Pharmaceuticals Corporation Pyridine N-oxide compounds as phosphodiesterase 4 inhibitors
MXPA05010373A (es) 2003-04-01 2005-12-05 Applied Research Systems Inhibidores de fosfodiesterasas en infertilidad.
MA41051B1 (fr) 2014-10-06 2020-11-30 Vertex Pharma Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
CA3019380A1 (fr) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique
CN109803962B (zh) 2016-09-30 2022-04-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物
MD3551622T2 (ro) 2016-12-09 2021-03-31 Vertex Pharma Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
JP7121794B2 (ja) 2017-08-02 2022-08-18 バーテックス ファーマシューティカルズ インコーポレイテッド ピロリジン化合物を調製するためのプロセス
WO2019079760A1 (fr) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Formes cristallines et compositions de modulateurs de cftr
EP3720849A2 (fr) 2017-12-08 2020-10-14 Vertex Pharmaceuticals Incorporated Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (fr) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263495B (fr) * 1992-12-23 1995-11-21 Celltech Ltd
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation

Also Published As

Publication number Publication date
AU1028097A (en) 1997-07-14
JP3465825B2 (ja) 2003-11-10
EP0873311A1 (fr) 1998-10-28
CA2238875A1 (fr) 1997-06-26
JP2000501742A (ja) 2000-02-15
WO1997022586A1 (fr) 1997-06-26
AU707574B2 (en) 1999-07-15

Similar Documents

Publication Publication Date Title
US5710170A (en) Tri-aryl ethane derivatives as PDE IV inhibitors
CA2238875C (fr) Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv
US5710160A (en) Diphenyl pyridyl ethane derivatives as PDE IV inhibitors
US6020339A (en) Aryl furan derivatives as PDE IV inhibitors
US6204275B1 (en) PDE IV inhibiting compounds, compositions and methods of treatment
US6034089A (en) Aryl thiophene derivatives as PDE IV inhibitors
US5962492A (en) 2 cyclo(alkyl and alkenyl) phenyl-alkenylyl heteroaryl compounds and pharmaceutical compositions containing same
CZ373096A3 (en) Trisubstituted phenyl derivatives, process of their preparation and pharmaceutical compositions containing thereof
CA2372426A1 (fr) Derives de pyridine heterosubstitues, en tant qu'inhibiteurs de pde 4
US6200993B1 (en) Heterosubstituted pyridine derivatives as PDE4 inhibitors
US6180650B1 (en) Heterosubstituted pyridine derivatives as PDE 4 inhibitors
AU732406B2 (en) Aryl thiophene derivatives as PDE IV inhibitors
CA2239053C (fr) Derives d'ethane diphenyle pyridyle utilises comme inhibiteurs de pde iv

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed